What is Immunocore?
Founded in 2008 and headquartered in Milton, United Kingdom, Immunocore is a specialized biotechnology firm focused on the development of novel biological drugs. The company's core competency lies in its unique soluble T-cell receptor (TCR) technology, which is designed to recognize and target intracellular proteins that are otherwise invisible to the immune system. This platform provides a versatile foundation for addressing high-unmet-need indications, ranging from aggressive cancer types to chronic infectious diseases.
As a clinical-stage organization, Immunocore operates at the intersection of advanced immunology and pharmaceutical engineering. Its market position is defined by its ability to translate complex scientific research into scalable therapeutic candidates, supported by a sophisticated intellectual property portfolio and strategic alliances with global biopharmaceutical leaders.
How much funding has Immunocore raised?
Immunocore has raised a total of $822.1M across 4 funding rounds:
Series A
$320M
Series B
$130M
Series C
$75M
Stock Offering
$297.1M
Series A (2015): $320M with participation from Malin Corporation plc, woodford investment management, eli lilly and company, and RTW Funds
Series B (2020): $130M led by Terra Magnum Capital Partners, China Construction Bank, Rock Springs Capital, General Atlantic LLC, Eli Lilly and Company, RTW Investments, JDRF T1D Fund, WuXi AppTec, and Bill & Melinda Gates Foundation
Series C (2021): $75M supported by BlackRock
Stock Issuance/Offering (2021): $297.1M, investors not publicly disclosed
Key Investors in Immunocore
General Atlantic LLC
General Atlantic is a global growth equity firm that provides capital and strategic support to high-growth companies in sectors such as healthcare, life sciences, and technology.
Eli Lilly and Company
Eli Lilly and Company is a global biopharmaceutical firm engaged in the discovery, development, and commercialization of prescription medicines, with a strong focus on oncology and immunology.
RTW Investments
RTW is a life sciences investment and innovation firm that focuses on biotech and medtech innovation throughout the entire lifecycle, providing both capital and deep scientific expertise.
What's next for Immunocore?
Looking ahead, the infusion of capital from the latest funding round is expected to accelerate the clinical development of Immunocore's lead programs. The strategic focus will likely center on expanding the reach of its TCR-based therapies through rigorous clinical trials and potential regulatory filings. Furthermore, the company is well-positioned to leverage its existing partnerships to enhance manufacturing capabilities and commercial readiness.
The firm's roadmap involves not only the advancement of its current pipeline but also the potential exploration of new therapeutic modalities. By maintaining a disciplined approach to research and development, Immunocore aims to solidify its status as a cornerstone of modern immunotherapy, ultimately driving long-term value for stakeholders and improving clinical outcomes for patients worldwide.
